pateclizumab
mAbexperimental
Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00888745)
Timeline
Indications
Studied for
Mechanism of action
- TNF-betaINHIBITOR
LTA inhibitor
Binds LT-alpha in both the secreted LT-alpha3 and the surface-expressed LT-alpha1beta2, blocking TNFR and LTBR signalling. Depletes LT-alpha¿expressing cells by antibody-dependent cellular cytotoxicity (ADCC).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPateclizumab ↗
- ChEMBLCHEMBL1743066 ↗
- ChEMBLCHEMBL1743056 ↗
Also known as
- mlta3698a
- mlta3698a
- mlta-3698a
- pateclizumab
- pateclizumab
- pro283698
- pro-283698
- rg-7415
- rg-7416
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01225393 | Phase 2 | Nov 1, 2010 | Genentech |
| NCT00888745 | Phase 1 | May 1, 2009 | Genentech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 2 | 2 | 2 | 2009 |
1 organizations
Page 1 / 1